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Resistance to artemisinin casts a shadow on the fight against malaria. The importance of illegal gold miners and of
malaria in isolated regions of French Guiana constitutes a threat that endangers the fight against malaria in the
Amazon. The hurdles of French laws and the remoteness of the territory from France make it impossible for the
system to adapt to the problem of total inaccessibility of an important part of the malaria problem. Transmission is
high in these areas and gold miners self-medicate with erratic regimens of artemisinin combinations, thus creating
perfect conditions for the emergence of resistance. What needs to be done is being done, but within the limits of
national law, with some results. However, facing the same difficult problem, Suriname shows more flexibility and is
doing much better than French Guiana despite having lower resources. Local authorities in French Guiana cannot
overrule the laws that block appropriate malaria care from reaching a third of malaria-exposed persons. Thus the
health authorities in France should take immediate calibrated legislative and financial measures to avoid a
predictable disaster.Background
Encouraged by the last decade’s funding efforts and sig-
nificant successes, malaria elimination has become a ser-
ious goal. In the past, such efforts have stumbled on the
rise of resistance to anti-malarials and insecticides that
affected the sustainability of the progresses made. Now,
the recent successes of artemisinin-based combinations
are increasingly threatened by the spread of artemisinin
resistance [1,2], thus casting a shadow on recent optimism.
In the late 1950s, shortly after WHO embarked on the
malaria eradication programme, resistance of Plasmodium
falciparum to chloroquine emerged on the Thai-Cambodia
border and spread throughout Asia and then Africa within
decades. Resistance to chloroquine also appeared inde-
pendently in the Amazon Basin. The same pattern hap-
pened again for the next anti-malarial drug, sulphadoxine+
pyrimethamine. The emergence was in Southeast Asia
and it spread towards Africa. Again, resistance independ-
ently appeared in the Amazon Basin and spread to the* Correspondence: mathieu.nacher66@gmail.com
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reproduction in any medium, provided the orsubcontinent. Now the hopes of controlling and eliminat-
ing malaria are threatened by resistance against artemisi-
nin derivatives, which has emerged and is spreading in
Southeast Asia [1-3]. There are reasons to fear that it
will also emerge in the Amazon Basin which holds 98%
of P. falciparum malaria cases in South America, and
notably the Guiana shield where the majority of cases
are concentrated [4].Looking for gold, finding malaria
Throughout the Amazon Basin, there has been remark-
able progress in controlling malaria. However, the problem
of mobile populations, such as miners, poses a challenge in
the region. An additional challenge is that these mobile
populations cross borders, and thus interventions of the
different countries should be coherent and coordinated in
order to treat the problem globally. The common features
of Southeast Asia and the Amazon are that malaria trans-
mission often affects remote forested areas where the
reach of health care systems is challenged. In addition,
the people affected are often mobile and engaged in il-
legal activities, such as gold or gem mining, logging or
fighting. In these areas there is no vector control, and ill
persons often self medicate with erratic drug regimens,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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this the situation in South America seems to be better
than in Southeast Asia [5,6].
There are reasons to believe that resistance to artemi-
sinin will appear in Europe’s own back yard. Following
the recent global economic meltdown, the price of gold
has sky rocketed, thus fuelling another gold rush. There
are gold miners, and there is malaria in the Amazon
and the Guianas. An estimated 10,000-15,000 garimpeiros
mostly originating from northern Brazil illegally operate
in French Guiana with profound consequences on human
health, the environment, security and the economy [7]. The
garimpeiros’s health-seeking behaviour in French Guiana
is not uniform. First, they are often far away from health
structures. Both Suriname [4] and Brazil report that a
significant number of people cross the border to get di-
agnosed and treated for malaria, allegedly to avoid being
arrested in French villages by the authorities. When they
get malaria, part of the treatment they receive is taken
and part is reportedly sold back on the mining sites in
exchange for gold. Remote health centres in French
Guiana also report treating garimpeiros with falciparum
malaria using Riamet® (fixed combination of artemether-
lumefantrine, Novartis). Finally, gold miners also have
access to artemisinin-based combination of unknown
origin (Artecom® is neither commercialized in Suriname,
in French Guiana nor in Brazil) on the gold mining
sites, as was observed during “Harpie” operations by the
French military.
Neighbouring successes and French legal constraints
Fighting malaria in mobile populations, hidden in the
tropical forest, is a very difficult challenge, for all health
delivery systems. The problem is compounded by the
fact that it affects border areas. Although there is an
effort to cooperate in the region, countries have differ-
ent strategies and different constraints, and different
results. Facing the same problem as French Guiana,
neighbouring Suriname has implemented an integrated
comprehensive programme funded by the global fund
that has been followed by remarkable success, with the
objective of malaria elimination now in sight. However,
the malaria problem originates largely outside of the
Surinamese territory, with most of the malaria cases
reported in the Surinamese clinics in fact coming from
French Guiana, thus potentially threatening the sus-
tainability of malaria control and derailing the object-
ive of elimination. With the “looking for gold, finding
malaria” programme, Suriname has used a community-
based approach with 31 malaria service deliverers working
on the gold mining sites and trained in prevention, the
use of rapid diagnostic tests, and the prompt delivery
of quality controlled artemisinin combinations for mal-
aria patients; this programme has been successful [8].In addition, active case detection is performed which
allows the interruption of transmission. France, how-
ever, cannot reach these invisible populations living in
areas beyond the rule of law. Although malaria cases
often seek treatment in Suriname or Brazil, some pa-
tients are treated by artemisinin combinations deliv-
ered by the health centres attached to Cayenne General
Hospital. Patients can even benefit from costly helicop-
ter evacuations (the first cause of emergency calls
and evacuations is fever) and receive optimal treatment
by infectious disease specialists. However, the core of mal-
aria transmission and of systematic self-medication is cur-
rently not tackled by the health system. While Suriname
showed flexibility, with a special focus on mobile popula-
tions, by relying on malaria service deliverers, France is
constrained by national and European laws that are quite
unfitting for the realities of this particular problem. In
France, it is illegal for someone who is not a certified
health professional to perform a rapid diagnostic test
(in 2007, a decree authorized nurses or personnel from
health centers to use the tests) or to prescribe a treat-
ment. There have been various successful interventions
relying on community-based approaches with trained non-
professionals delivering malaria treatment [9-11], but
this is not yet feasible, because not authorized in French
Guiana. For health structures, sending health profes-
sionals to illegal gold mining sites is unlikely to ever
take place: security there is not assured and it is prob-
able that garimpeiros would believe public health workers
to be no different than the government that sends forces
to dismantle gold mining sites, which could put them
at risk.
Thus, the fight against malaria is bound to fail if it
just continues to follow the current national laws and
regulations.
Beyond the rule of law, research and action are
unauthorized
The recent emergence of artemisinin resistance in
P. falciparum in western Cambodia was detected by
showing a significant reduction in parasite clearance rates
and increased failure rates following artemisinin com-
bination treatment. In addition to treatment failures and
pharmacokinetic data, WHO currently recommends meas-
uring parasite density at day 0, day 2 and day 3. The pro-
portion of patients with a persistent parasitaemia at
day 3 is a good indicator to exclude the presence of
resistance. However, it is not adapted to define resist-
ance because it depends on the initial parasite density,
the timing of the sample and it requires large sample
sizes. One of the pillars of the global plan to contain
artemisinin resistance is to intensify monitoring and
surveillance [12]. There are no reliable genetic markers
for artemisinin resistance yet. For a precise assessment
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ing of malaria parasite clearance rate, plus a follow up
for a minimum of 28 days is required [13]. To do the
same in France, as of today, it would be very expensive
to occupy expensive hospital beds to keep patients
hospitalized and legally complicated, if not illegal. The
public health law forbids the conduct of interventional
research on patients that do not have health insurance
because, theoretically, fear of not getting treatment could
coerce patients to participate in research programmes. A
new law, the Jardé law, relaxes that barrier. However, the
application decrees are not published yet and, until then,
the Institutional Review Board’s in France still follow the
Huriet Serusclat law that forbids biomedical research in
persons without health insurance. For clinicians, who are
in insufficient numbers in French Guiana, it seems unreal-
istic to expect them to decrypt the multilayered opaque
French regulations that thus stand in the way of a precise
assessment of resistance.
Why is it so difficult to do what needs to be done?
The voice of French Guiana does not weigh much when
European and French laws are voted. From Paris, it is
hard to imagine that while at the European space port
the business is booming for Arianespace, Europe is also
preparing the malaria parasites of tomorrow.
For malaria experts coming from areas where most
malaria detection and treatment is performed by non-
doctors, the response to the malaria problem in French
Guiana, a rich country, often seems puzzling: why is there
no active case detection? Why does France make it so
difficult to treat with primaquine (although the High
Council for Public Health advising the Ministry of Health
recommended it, it could only wish that a company would
volunteer to initiate the process for official approval…
meanwhile, some paper work and, in practice, 48 hours
are necessary to obtain it), or to deal with the problem
of malaria in gold miners? There is some schizophrenia
in the state agencies with law enforcement clashing
with public health. It is not that nothing is being done.
Insecticide-treated bed nets have been funded and dis-
tributed; vector control teams are present in the villages;
infectious disease specialists care for the patients seen
at the hospital, Institut Pasteur does in vitro surveillance
of drug resistance, the incidence of malaria has been di-
vided by three in the villages of French Guiana, the re-
gional health agency has actively pursued a regional
approach with neighbouring countries. But much of the
problem originates from the illegal mining sites, and
the legal framework of France is not adapted for such a
situation. Although the health regional agencies have
benefitted from decentralized powers, they do not have
the power to bypass the law, even when it is obviously
not adapted to the context.Presently, about 30,000 legal residents live in the
endemic areas of French Guiana, but there are up to
15,000 illegal miners. Thus, although WHO recommends
100% coverage of exposed populations by appropriate
interventions, in French Guiana it is more like two thirds
of the population benefitting from a malaria programme
with appropriate interventions. The rest are attempting
to self medicate the problem away. Cross border ef-
forts are not proportional. On one side of the border
Suriname is following the WHO policy, on the other
side France is not. Therefore, if the status quo is maintained
it would be illusory to think that malaria will ever be
eliminated from French Guiana, thus from the neighbouring
countries of Brazil and Suriname. In the past, despite
greater malaria incidence, little has been done to tackle
this problem. The recent decline of malaria incidence in
the villages of French Guiana will definitely not be a
stimulant to make some changes: everything seems to
be going well, while an invisible third of the problem is
out of control.
What could be done? Special derogations, special funds
and special implementing structures for a special
problem
What needs to be done is known but it cannot be done
in France, under national laws.
Reaching populations
If the health system cannot go to the gold mines, and
since the gold miners would probably not spontaneously
go to the military health professionals, there needs to be
some way to improve detection and treatment of malaria
on site. NGOs could be a solution to fill that gap. Given
the number of mining sites, and their scattered loca-
tions, to cover all the ground simultaneously would be
difficult and costly. Médecins du Monde, which already
operates in French Guiana delivering health care for urban
migrants, or Médecins sans Frontières, could be better
suited to approach this problem than the official health
system and its constraints. But these French NGOs may
not be willing to intervene, and probably even less so in
the absence of specific funds. If “professional” NGOs do
not intervene, exceptional measures should allow local
health authorities to implement community-based actions
even if they go against some of the laws voted far away
from the forests of French Guiana. Exceptional measures
now, not in five years.
WHO recommends universal coverage with appropri-
ate interventions for the entire population at risk, for
prevention, diagnosis and treatment. It also emphasizes
a special effort to ensure that the most vulnerable popu-
lations are covered. WHO also recommends strong lead-
ership at the ministerial level (funding, regulations). For
French Guiana, the Ministry is in Paris, malaria may not
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calibrated response to the financial and regulatory bar-
riers that prevent the fight against malaria to reach
universal coverage.
Implementing structure
Perhaps the dispersion of health and research profes-
sionals in different institutions with different scientific
pursuits and a variety of other problems to deal with is
detrimental to achieve a clear focus and timely response
towards the goal of controlling malaria in gold mining
areas. The interventions to reach these populations should
be a cross border effort since garimpeiros are highly mo-
bile. The absence of a programme manager also compli-
cates the international coordination with other national
malaria programmes dealing with the same problem.
The creation of an implementing structure with a voice,
staff, and sufficient funds to achieve strategic goals with
regards to malaria could hence facilitate this task. How-
ever, if the legal obstacles for the health system to reach
gold miners remain, the added value would be marginal,
because a third of the malaria problem, the most diffi-
cult third, would still not be properly dealt with.
There has been enduring concern about the emer-
gence of unknown new pathogens from the Amazonian
biodiversity hotspot [14]. One that is likely to emerge is
artemisinin-resistant P. falciparum. Something should be
done about it. Something should have been done about
it much earlier because neither malaria, gold mining nor
resistance to anti-malarials are particularly new [15]. In
November 2012, it was reported that in Suriname, near
the border with French Guiana, up to 31% of patients still
had detectable parasites at day 3 after Coartem® treatment
[16,17]. This needs to be confirmed, but the fear may have
become reality and further delays would be disastrous.
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